N-Acetyl-Semax

Intranasal administration is the primary route. Common research formulations: 0.1% (10 mg/10 ml) and 0.3% (30 mg/10 ml) nasal sprays delivering ~300 mcg per spray. Typical research dosing is 200-600 mcg/day intranasally. The N-Acetyl Amidate form is considered to have improved pharmacokinetics compared to base Semax. Clinical use is primarily in Russia and Eastern Europe.

Rapidly elevates brain-derived neurotrophic factor (BDNF) levels by approximately 1.4x and doubles expression of TrkB receptors in the hippocampus, promoting neuroplasticity and neurogenesis.

Activates dopaminergic and serotonergic brain systems, which may underlie its cognitive-enhancing and mood-modulating effects.

Inhibits enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, potentially modulating pain perception and mood.

Increases nerve growth factor (NGF) levels, contributing to neuroprotection and nerve repair processes.

Demonstrated nootropic effects including improved memory, attention, and learning in both animal models and limited human studies. Used clinically in Russia for cognitive disorders.

Provides neuroprotective effects against oxidative stress and ischemic damage, with potential applications in stroke recovery and neurodegenerative conditions.

May reduce anxiety and improve mood through serotonergic and dopaminergic system modulation, though robust clinical trial data is limited.

Promotes nerve repair and regeneration through BDNF and NGF upregulation, potentially aiding recovery from brain injury.

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) that encompasses the sequence 4-7 of N-termina...

Journal of inorganic biochemistry · Antonio Magrì, Giovanni Tabbì, Alessandro Giuffrida, Giusepp...